Axogen jumped over 8% pre-market after the FDA approved Avance, its acellular nerve scaffold for treating sensory, mixed, and motor peripheral nerve discontinuities in adults and children. Retail sentiment on Stocktwits turned extremely bullish, with message volumes spiking to extremely high levels.